People 50 and older have a lot to look forward to, according to Juvenescence’s Greg Bailey—mainly that we won’t be aging as fast or poorly as our parents. “Science fiction has become science,” said the UK-based anti-aging biotech’s CEO about the company’s completing its $100 million Series B round of financing last week. “I think the world is going to be shocked,” he said in an interview. In total, Juvenescence has now raised $165 million in just 18 months to fund longevity projects with the lofty goal of extending human lifespans to 150 years.
From programmable pills to power-generating boots, here are some of the most unusual technological innovations we covered this year.
We are all about emerging technologies here at Tech Review—including those that might never make it past the “emerging” stage. Here are some of the more recondite inventions we have covered this year, many of them plumbed from the arXiv, the pre-publication academic paper database.
As the average age in developed economies rises in the coming years and decades, one of the next big economic disruptions may be in anti-aging medicines, according to a report by Citi.
Why it matters: Already, the anti-aging market is about $200 billion, and the new boom could be in drugs that slow, reverse or prevent age-related disease, Citi says. On the other hand, if people are aging more slowly, and diseases are slowed or prevented, then other drugs, treatments and surgeries, which earn billions of dollars, may not be necessary.
Pills hailed as the first real “anti-aging” drugs inched a little closer to the market after a study found they cut the number of respiratory infections in the elderly by half.
The drugs: The pills act on an aging-related pathway called TORC1. Inhibiting this pathway “has extended life span in every species studies to date,” according to Joan Mannick, who led the study for drug giant Novartis. Those species include mice and worms.